Skip to content

NIHR

James Lind Alliance Priority Setting Partnerships Rolling Funding Opportunity

Rolling funding opportunity; no fixed deadline stated

Last updated:

No deadline is on file for this call. Check NIHR's own call page for the current round's status before you plan around it.

Is this grant right for you? Check your personalised match score. 30s, no email. See my matches →

The James Lind Alliance Priority Setting Partnerships Rolling Funding Opportunity through NIHR's EME Programme funds clinical and mechanistic studies directly aligned to patient-defined research priorities. The call is open to UK-based researchers pursuing hypothesis-driven projects with proof of concept in humans and mandatory patient and public involvement from the outset. Clinical trials must meet UK Medicines for Human Use regulations, with support from UKCRC Clinical Trials Units recommended.

Details

Funder NIHR
Application Outline application → Full application
Frequency Continuous
Eligible countries GB

Eligibility & scope

HTA Programme rolling call for research addressing priorities identified through James Lind Alliance Priority Setting Partnerships. Applicants must be UK-based and address NHS or social care populations using PICO framework. Research must demonstrate the intervention is ready for HTA evaluation via evidence synthesis.

Who Should Apply

  • UK-based clinical and academic researchers with proof-of-concept data in human participants
  • Teams including patient and public partners from application design stage onwards
  • Researchers working on topics identified in JLA Priority Setting Partnership consultations
  • Trialists prepared to engage UKCRC Clinical Trials Units or equivalent governance infrastructure

Key Dates

  • Rolling deadline, applications accepted continuously
  • Two-stage process: outline application followed by full application
  • UK-only eligible sites

Tips for Applicants

  • Align your research question explicitly to a published JLA Priority Setting Partnership topic; misalignment is a major rejection driver.
  • Patient and public co-applicants or co-investigators strengthen the application; NIHR reviewers verify involvement at outline stage.
  • For clinical trials, confirm CTU support or governance route early, absence of a named trials unit weakens competitive position.

Frequently Asked Questions

What is the James Lind Alliance Priority Setting Partnership funding for?

It funds clinical and mechanistic research studies directly addressing research questions prioritised by patients and the public through JLA Priority Setting Partnership consultations. Projects must include proof of concept in humans and be hypothesis-driven.

Do I need patient involvement to apply for NIHR EME?

Yes, patient and public involvement is mandatory from the outset, it must be embedded in the research design, not added later.

Can I apply if my institution is outside the UK?

No, the James Lind Alliance EME Programme is a domestic UK funding opportunity; all applicants and host institutions must be UK-based.

What is the application process for NIHR EME funding?

Applications follow a two-stage process: you first submit an outline application, and if successful, you then develop and submit a full application.

Do clinical trials need ethics and regulatory approval?

Yes, clinical trials must comply with the UK Medicines for Human Use (Clinical Trials) Regulations 2004, and involvement of a UKCRC Clinical Trials Unit is recommended to manage governance.

nihreme-programmeclinical-trialspatient-involvementuk-domestichypothesis-drivenpriority-setting

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

Browse Related

Could James Lind Alliance Priority Setting Partnerships Rolling Funding Opportunity be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →